Literature DB >> 2647104

Noradrenaline release and the pathophysiology of primary human hypertension.

M Esler1, G Jennings, G Lambert.   

Abstract

Measurements of the overflow of norepinephrine to plasma from individual organs (using radiotracer methodology) were used to delineate the pattern of sympathetic nervous system activation present in primary human hypertension. Mean total norepinephrine (NE) spillover in hypertensive patients was 418 ng/min, 42% (124 ng/min) higher than in subjects with normal blood pressure (BP)(P less than .05). Norepinephrine spillover among hypertensive patients was a function of age, only being elevated in patients under 40 years of age. Half of the excess in total norepinephrine release in hypertensive patients was accounted for by increased cardiorenal spillover. Mean renal norepinephrine spillover was 120 ng/min, compared with 69 ng/min in healthy subjects (P less than .02). Renal spillover was highest in younger patients. Corresponding cardiac norepinephrine spillover values were 12.6 ng/min and 5.1 ng/min (P less than .01). The balance of the excess total norepinephrine spillover comes from undetermined sites, but not the lungs or hepatomesenteric circulation. These measurements of regional norepinephrine overflow suggest that sympathetic nervous outflow to the kidneys and heart is selectively activated in early hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647104     DOI: 10.1093/ajh/2.3.140s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  26 in total

Review 1.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

2.  Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.

Authors:  Yumi Koike; Tetsuya Kawabe; Kanami Nishihara; Naomi Iwane; Takuzo Hano
Journal:  Hypertens Res       Date:  2016-07-21       Impact factor: 3.872

Review 3.  Renal sympathetic denervation: applications in hypertension and beyond.

Authors:  Michael Böhm; Dominik Linz; Daniel Urban; Felix Mahfoud; Christian Ukena
Journal:  Nat Rev Cardiol       Date:  2013-06-18       Impact factor: 32.419

Review 4.  How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?

Authors:  Kui Toh Gerard Leong; Henry Krum
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

5.  CrossTalk opposing view: Which technique for controlling resistant hypertension? Renal nerve ablation.

Authors:  Markus P Schlaich; Yusuke Sata; Murray D Esler
Journal:  J Physiol       Date:  2014-09-15       Impact factor: 5.182

6.  Single-unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover.

Authors:  Elisabeth A Lambert; Markus P Schlaich; Tye Dawood; Carolina Sari; Reena Chopra; David A Barton; David M Kaye; Mikael Elam; Murray D Esler; Gavin W Lambert
Journal:  J Physiol       Date:  2011-03-14       Impact factor: 5.182

7.  Quantification of Renal Sympathetic Vasomotion as a Novel End Point for Renal Denervation.

Authors:  Peter Ricci Pellegrino; Irving H Zucker; Yiannis S Chatzizisis; Han-Jun Wang; Alicia M Schiller
Journal:  Hypertension       Date:  2020-08-24       Impact factor: 10.190

Review 8.  Renal nerves in the maintenance of hypertension: a potential therapeutic target.

Authors:  Richard E Katholi; Krishna J Rocha-Singh; Nilesh J Goswami; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

Review 9.  Renal denervation in human hypertension: mechanisms, current findings, and future prospects.

Authors:  Markus P Schlaich; Dagmara Hering; Paul A Sobotka; Henry Krum; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 10.  Secondary hypertension. An overview of its causes and management.

Authors:  D H Streeten; G H Anderson
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.